People news: Savient and Lilly Oncology

Share this article:
John Johnson, SVP and president of Lilly Oncology, has resigned from the company effective January 28. He will join New Jersey-based Savient Pharmaceuticals as the company's CEO, effective January 31. Johnson's decision to resign was “driven by personal and family considerations,” according to a Lilly statement. Johnson, formerly CEO of ImClone, became SVP and president of Lilly Oncology following Lilly's acquisition of ImClone in 2008. Prior to ImClone, Johnson served as company group chairman of J&J's worldwide biopharmaceuticals unit.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions